liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Show others and affiliations
2019 (English)In: Cancer Letters, ISSN 0304-3835, E-ISSN 1872-7980, Vol. 448, p. 70-83Article in journal (Refereed) Published
Abstract [en]

Proteasome inhibitors have been shown to induce cell death in cancer cells by triggering an acute proteotoxic stress response characterized by accumulation of poly-ubiquitinated proteins, ER stress and the production of reactive oxygen species. The aggresome pathway has been described as an escape mechanism from proteotoxicity by sequestering toxic cellular aggregates. Here we show that b-AP15, a small-molecule inhibitor of proteasomal deubiquitinase activity, induces poly-ubiquitin accumulation in absence of aggresome formation. b-AP15 was found to affect organelle transport in treated cells, raising the possibility that microtubule-transport of toxic protein aggregates is inhibited, leading to enhanced cytotoxicity. In contrast to the antiproliferative effects of the clinically used proteasome inhibitor bortezomib, the effects of b-AP15 are not further enhanced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Our results suggest an inhibitory effect of b-AP15 on the transport of misfolded proteins, resulting in a lack of aggresome formation, and a strong proteotoxic stress response.

Place, publisher, year, edition, pages
ELSEVIER IRELAND LTD , 2019. Vol. 448, p. 70-83
Keywords [en]
Ubiquitin-proteasome system; Deubiquitinase; UPS inhibitor
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-156592DOI: 10.1016/j.canlet.2019.02.003ISI: 000463129800008PubMedID: 30768956OAI: oai:DiVA.org:liu-156592DiVA, id: diva2:1315592
Note

Funding Agencies|Radiumhemmets Forskningsfonder [154193]; Cancerfonden [15 0818]; Vetenskapsradet [2015-02905]; Barncancerfonden [2015-0091]; Knut och Alice Wallenbergs Stiftelse [2015.0063]

Available from: 2019-05-14 Created: 2019-05-14 Last updated: 2019-06-28

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Mofers, ArjanSelvaraj, KarthikLinder, StigD´arcy, Padraig
By organisation
Division of Drug ResearchFaculty of Medicine and Health Sciences
In the same journal
Cancer Letters
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf